Regeneron Pharmaceuticals (NASDAQ:REGN) Price Target Raised to $975.00

Regeneron Pharmaceuticals (NASDAQ:REGN) had its price objective boosted by investment analysts at Guggenheim from $865.00 to $975.00 in a report issued on Monday,Benzinga reports. The firm currently has a “buy” rating on the biopharmaceutical company’s stock. Guggenheim’s target price suggests a potential upside of 24.85% from the stock’s previous close.

A number of other analysts have also weighed in on the company. Bank of America upgraded Regeneron Pharmaceuticals from an “underperform” rating to a “buy” rating and upped their target price for the stock from $627.00 to $860.00 in a report on Wednesday, January 7th. JPMorgan Chase & Co. upped their price objective on Regeneron Pharmaceuticals from $850.00 to $950.00 and gave the stock an “overweight” rating in a research note on Monday, February 2nd. Cantor Fitzgerald raised their price objective on Regeneron Pharmaceuticals from $740.00 to $800.00 and gave the company an “overweight” rating in a research report on Monday, February 2nd. Truist Financial decreased their price target on shares of Regeneron Pharmaceuticals from $820.00 to $818.00 and set a “buy” rating for the company in a research report on Monday, February 2nd. Finally, Citigroup lifted their price objective on shares of Regeneron Pharmaceuticals from $660.00 to $700.00 and gave the stock a “buy” rating in a research report on Wednesday, October 29th. Three equities research analysts have rated the stock with a Strong Buy rating, fourteen have given a Buy rating and eight have issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $793.81.

Regeneron Pharmaceuticals Stock Down 0.6%

Shares of Regeneron Pharmaceuticals stock traded down $4.59 during trading on Monday, hitting $780.92. 53,519 shares of the stock traded hands, compared to its average volume of 867,906. The company has a current ratio of 4.13, a quick ratio of 3.39 and a debt-to-equity ratio of 0.09. The stock’s fifty day simple moving average is $757.29 and its 200 day simple moving average is $658.82. The firm has a market cap of $82.08 billion, a P/E ratio of 18.86, a price-to-earnings-growth ratio of 2.11 and a beta of 0.40. Regeneron Pharmaceuticals has a 52-week low of $476.49 and a 52-week high of $821.11.

Regeneron Pharmaceuticals (NASDAQ:REGN) last released its quarterly earnings data on Friday, January 30th. The biopharmaceutical company reported $11.44 earnings per share for the quarter, topping analysts’ consensus estimates of $10.74 by $0.70. Regeneron Pharmaceuticals had a net margin of 31.41% and a return on equity of 13.04%. The company had revenue of $3.88 billion during the quarter, compared to analyst estimates of $3.76 billion. During the same period in the prior year, the firm earned $12.07 earnings per share. The firm’s revenue for the quarter was up 2.5% compared to the same quarter last year. On average, equities analysts predict that Regeneron Pharmaceuticals will post 35.92 earnings per share for the current fiscal year.

Insider Transactions at Regeneron Pharmaceuticals

In related news, Director Bonnie L. Bassler sold 1,500 shares of the firm’s stock in a transaction on Wednesday, January 7th. The stock was sold at an average price of $800.00, for a total value of $1,200,000.00. Following the completion of the transaction, the director owned 1,703 shares in the company, valued at $1,362,400. This trade represents a 46.83% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. 7.02% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the company. Dodge & Cox increased its stake in shares of Regeneron Pharmaceuticals by 64.6% in the second quarter. Dodge & Cox now owns 3,826,283 shares of the biopharmaceutical company’s stock worth $2,008,799,000 after acquiring an additional 1,502,198 shares during the period. Norges Bank purchased a new stake in Regeneron Pharmaceuticals in the second quarter valued at $628,151,000. AQR Capital Management LLC grew its position in Regeneron Pharmaceuticals by 528.7% during the 3rd quarter. AQR Capital Management LLC now owns 721,354 shares of the biopharmaceutical company’s stock worth $405,596,000 after purchasing an additional 606,612 shares during the period. Invesco Ltd. raised its stake in shares of Regeneron Pharmaceuticals by 38.0% during the 3rd quarter. Invesco Ltd. now owns 1,484,473 shares of the biopharmaceutical company’s stock valued at $834,675,000 after buying an additional 408,649 shares during the last quarter. Finally, Acadian Asset Management LLC lifted its holdings in shares of Regeneron Pharmaceuticals by 234.7% in the 2nd quarter. Acadian Asset Management LLC now owns 465,740 shares of the biopharmaceutical company’s stock valued at $244,480,000 after buying an additional 326,583 shares during the period. 83.31% of the stock is currently owned by hedge funds and other institutional investors.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.